P. J. Converse

Direct inhibitors of InhA with efficacy similar or superior to isoniazid in novel drug regimens for tuberculosis

This study evaluates direct inhibitors of InhA (DIIs) for tuberculosis treatment, showing their efficacy comparable to isoniazid and their potential in new drug regimens.

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

This study evaluates the efficacy of ultrashort telacebec treatment in mouse models of Buruli ulcer, finding that total dose is more critical than duration and that resistance can emerge in immunocompromised hosts.

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.